GlassScriptPhysician profile
Cai Yuan
NPI 1215341516
$1,787.24
in general payments reported to CMS, 2019-2025
19 companies · $828 in 2025
The $828 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $180 · 2023: $178 · 2024: $602 · 2025: $828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,561 · Education: $45.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,561.05 |
| Education | $45.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $512.45 | 2024-2025 | |
| Pfizer INC. | $311.04 | 2023-2025 | |
| Celgene Corporation | $298.80 | 2022-2025 | Reblozyl |
| Astrazeneca Pharmaceuticals LP | $148.37 | 2024-2025 | Lynparza, Enhertu |
| Daiichi Sankyo INC. | $105.05 | 2024-2025 | Datroway, Enhertu, Injectafer |
| Ipsen Biopharmaceuticals, INC | $81.91 | 2025 | Onivyde |
| Stemline Therapeutics INC. | $49.15 | 2023-2024 | Orserdu |
| Astellas Pharma US INC | $42.20 | 2025 | Vyloy, Xtandi |
| Genmab U.S., INC. | $37.94 | 2024 | Epkinly, Tivdak |
| Abbvie INC. | $35.33 | 2024 | |
| Iovance Biotherapeutics, INC. | $22.30 | 2025 | Amtagvi |
| Genzyme Corporation | $21.31 | 2023 | |
| Regeneron Healthcare Solutions, INC. | $20.90 | 2023 | Libtayo |
| Aveo Pharmaceuticals, INC. | $20.00 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $18.05 | 2024 | Opdivo |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $17.95 | 2023 | Welireg, Keytruda, Lynparza |
| Immunocore Limited | $16.46 | 2025 | Kimmtrak |
| Tempus Ai, INC | $14.47 | 2024 | |
| Pharmacyclics LLC, An Abbvie Company | $13.56 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Cai Yuan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.